March 18 (Reuters) - Bristol-Myers Squibb Co :
* BRISTOL MYERS SQUIBB COMPLETES ACQUISITION OF KARUNA THERAPEUTICS, STRENGTHENING NEUROSCIENCE PORTFOLIO
* BRISTOL-MYERS SQUIBB CO: TRANSACTION TO RESULT IN ABOUT $12 BILLION ONE-TIME, NON-DEDUCTIBLE ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT CHARGE
* BRISTOL-MYERS SQUIBB CO: ACQUIRED IPR&D CHARGE TO IMPACT BOTH 2024 Q1 AND FULL-YEAR GAAP AND NON-GAAP EPS BY ABOUT $5.93
Source text for Eikon: Further company coverage:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments